CSIMarket Company Name, Ticker, Customers, else..
 
Waldencast Plc  (NASDAQ: WALD)
 
Price: $1.3700 $0.00 0.000%
Day's High: $1.3849999904632568 Week Perf: -1.44 %
Day's Low: $ 1.36 30 Day Perf: -4.86 %
Volume (M): 80,155 52 Wk High: $ 3.22
Volume (M$): $ 0 52 Wk Avg: $1.65
Open: $1.36 52 Wk Low: $0.72



 Market Capitalization (Millions $) 156
 Shares Outstanding (Millions) 114
 Employees 364
 Revenues (TTM) (Millions $) 272
 Net Income (TTM) (Millions $) -248
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Waldencast Plc is a multinational technology company that specializes in software development and IT consulting services. With a global presence, they cater to clients from various industries, including finance, healthcare, and manufacturing. Their team of highly skilled professionals has expertise in areas like cloud computing, big data analytics, and artificial intelligence. Waldencast Plc aims to provide innovative solutions that drive digital transformation and enhance business performance for their clients.


   Company Address: 81 Fulham Road London 0
   Company Phone Number: 3196 0264   Stock Exchange / Ticker: NASDAQ WALD


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
COTY        2.81% 
ULVR        2.81% 
HBIA   -0.32%    
MGRC   -0.61%    
PINS   -12.03%    
• View Complete Report
   



Merger and Acquisition

Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha, Under the Obagi Medical Brand A Strategic Shift Amid Leadership Changes,

Published Wed, Jul 23 2025 10:45 AM UTC

Waldencast s Strategic Acquisition: Strengthening Obagi Medical’s Injectable Portfolio Amidst Leadership ChangesIn a pivotal moment for both Waldencast and the evolving skincare landscape, the acquisition of Novaestiq Corp. and the U.S. rights to their popular injectable hyaluronic acid gel line, Saypha, is positioning Obagi Medical as a formidable player in the aesthetic ...
Management Changes

“Leadership Shake-Up at Waldencast: A Crucial Moment Amidst Financial Setbacks,

Published Mon, Oct 7 2024 9:10 PM UTC

Waldencast Plc: A Dual Narrative of Leadership Renewal and Financial Struggles Key Facts:1. Board Appointments: Waldencast plc has appointed three new directors — Hind Sebti, Kelly Brookie, and Roberto Thompson — effective September 26, 2024. Ms. Brookie will replace Sarah Brown, who chose not to renew her mandate ahead of the upcoming Annual General Meeting (AGM). 2. A...
Product Service News

Obagi Medical Launches New Skincare Products Amidst Waldencast Plcs Financial Struggles

Published Mon, Sep 9 2024 1:38 PM UTC

In the fast-evolving world of skincare and consumer products, Obagi Medical has unveiled two new additions to its lineup: the ELASTIDERM Lift Up & Sculpt Facial Moisturizer and the ELASTIDERM Advanced Filler Concentrate. These products promise to enhance skin elasticity and provide an advanced filler effect, catering to an increasingly discerning consumer base focused on ant...
Announcement

Rosen Law Firm Investigates Potential Securities Claims Against Waldencast PLC - Implications for Investors

Published Tue, Mar 12 2024 8:08 PM UTC

- March 12, 2024ROSEN, A LEADING LAW FIRM, Encourages Waldencast plc Investors to Inquire About Securities Class Action InvestigationNEW YORK, March 12, 2024 - Rosen Law Firm, a global investor rights law firm, is actively investigating potential securities claims against Waldencast PLC (NASDAQ: WALD, WALDW). The investigation is based on allegations that Waldencast may hav...
Product Service News

Obagi Cosmeceuticals Launches Rejuvenating Eye Gel Cream as Part of Daily Hydro-Drops Collection

Published Thu, Mar 7 2024 2:00 PM UTC

Obagi Cosmeceuticals, a renowned skincare brand, recently unveiled its latest addition to the Daily Hydro-Drops Collection: the Rejuvenating Eye Gel Cream. This newly launched product aims to provide customers with a powerful and effective solution for addressing under-eye concerns. By combining advanced ingredients with Obagi s commitment to quality, the Rejuvenating Eye Ge...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 0.57
Price to Sales (Expected) -
Price to Book 0.34
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.73
Working Capital Ratio 2.82
Leverage Ratio (MRQ) 0.62
Total Debt to Equity 0.32
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.01 $
Revenues (TTM) 2.38 $
Cash Flow (TTM) -
Cash 0.27 $
Book Value 4.05 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 747,302
Net Income per Employee (TTM) -681,473
Receivable Turnover Ratio (TTM) 9.67
Inventory Turnover Ratio (TTM) 1.76
Asset Turnover Ratio (TTM) 0.36

Profitability Ratios Current
Gross Margin (MRQ) 67.28 %
Operating Margin (MRQ) -79.97 %
Net Margin (MRQ) -91.19 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Waldencast Plc's Segments
Obagi Medical    59.42 % of total Revenue
Milk Makeup    40.6 % of total Revenue
Net product sales    98.59 % of total Revenue
Net product sales Obagi Medical    57.99 % of total Revenue
Net product sales Milk Makeup    40.6 % of total Revenue
Net product sales Direct sales    79.91 % of total Revenue
Net product sales Direct sales Obagi Medical    40.31 % of total Revenue
Net product sales Direct sales Milk Makeup    39.6 % of total Revenue
Net product sales Distributors    18.68 % of total Revenue
Net product sales Distributors Obagi Medical    17.68 % of total Revenue
Net product sales Distributors Milk Makeup    1 % of total Revenue
Royalties    1.43 % of total Revenue
Royalties Obagi Medical    1.43 % of total Revenue
United States Net product sales    75.18 % of total Revenue
Net product sales North America    77.93 % of total Revenue
Net product sales Rest of the World    20.66 % of total Revenue
Obagi    59.42 % of total Revenue

  Waldencast Plc Outlook

On March 21 2024 the Waldencast Plc provided following guidance


Walden...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.